中国8月龄婴儿同时接种麻风疹疫苗与减毒JE疫苗的免疫原性和安全性
在中国8个县区开展的多中心、开放标签、非劣效随机对照试验显示,8月龄婴儿同时接种麻风疹疫苗与SA 14-14-2减毒日本脑炎活疫苗后,麻疹和风疹的IgG抗体阳转率均非劣效于单独接种麻风疹疫苗,且两组不良事件无差异。
要点
- 8月龄同时接种麻风疹与JE疫苗不影响麻疹和风疹的免疫应答。
- 同时接种组与单独接种组不良事件发生率无差异,未发生严重不良事件。
- 结果为麻疹风疹消除和JE疫苗扩大接种提供依据。
核心结论
- 8月龄婴儿同时接种麻风疹疫苗与LJEV的免疫原性非劣效于单独接种麻风疹疫苗,且安全性良好。
研究设计与样本
- 多中心、开放标签、非劣效、两组随机对照试验,在中国8个县或区招募8月龄健康婴儿。
- 1093名婴儿入组,随机1:1分配至麻风疹+LJEV组(545名)或麻风疹组(548名),完成研究分别为507名和506名。
主要发现
- 两组均无严重不良事件,局部或全身不良事件发生率无差异;发热最常见(19% vs 21%)。
关键数值与推荐
- 非劣效界值为5%。
- 麻疹和风疹血清阳转的非劣效性均成立(90% CI下限高于-5%)。
临床怎么用
- 支持在中国8月龄婴儿中同时接种麻风疹疫苗和LJEV。
- 该证据有助于麻疹风疹消除和JE疫苗扩大接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In China, measles-rubella vaccine and live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) are recommended for simultaneous administration at 8 months of age, which is the youngest recommended age for these vaccines worldwide. We aimed to assess the effect of the co-administration of these vaccines at 8 months of age on the immunogenicity of measles-rubella vaccine. METHODS: We did a multicentre, open-label, non-inferiority, two-group randomised controlled trial in eight counties or districts in China. We recruited healthy infants aged 8 months who had received all scheduled vaccinations according to the national immunisation recommendations and who lived in the county of the study site. Enrolled infants were randomly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles-rubella plus LJEV group) or measles-rubella vaccine alone (measles-rubella group). The primary outcome was the proportion of infants with IgG antibody seroconversion for measles 6 weeks after vaccination, and a secondary outcome was the proportion of infants with IgG antibody seroconversion for rubella 6 weeks after vaccination. Analyses included all infants who completed the study. We used a 5% margin to establish non-inferiority. This trial was registered at ClinicalTrials.gov (NCT02643433). FINDINGS: 1173 infants were assessed for eligibility between Aug 13, 2015, and June 10, 2016. Of 1093 (93%) enrolled infants, 545 were randomly assigned to the measles-rubella plus LJEV group and 548 to the measles-rubella group. Of the infants assigned to each group, 507 in the measles-rubella plus LJEV group and 506 in the measles-rubella group completed the study. Before vaccination, six (1%) of 507 infants in the measles-rubella plus LJEV group and one (<1%) of 506 in the measles-rubella group were seropositive for measles; eight (2%) infants in the measles-rubella plus LJEV group and two (<1%) in the measles-rubella group were seropositive for rubella. 6 weeks after vaccination, measles seroconversion in the measles-rubella plus LJEV group (496 [98%] of 507) was non-inferior to that in the measles-rubella group (499 [99%] of 506; difference -0·8% [90% CI -2·6 to 1·1]) and rubella seroconversion in the measles-rubella plus LJEV group (478 [94%] of 507) was non-inferior to that in the measles-rubella group (473 [94%] of 506 infants; difference 0·8% [90% CI -1·8 to 3·4]). There were no serious adverse events in either group and no evidence of a difference between the two groups in the prevalence of any local adverse event (redness, rashes, and pain) or systemic adverse event (fever, allergy, respiratory infections, diarrhoea, and vomiting). Fever was the most common adverse event (97 [19%] of 507 infants in the measles-rubella plus LJEV group; 108 [21%] of 506 infants in the measles-rubella group). INTERPRETATION: The evidence of similar seroconversion and safety with co-administered LJEV and measles-rubella vaccines supports the co-administration of these vaccines to infants aged 8 months. These results will be important for measles and rubella elimination and the expansion of Japanese encephalitis vaccination in countries where it is endemic. FUNDING: US Centers for Disease Control and Prevention, US Department of Health and Human Services; China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases.
引用
- Li Y, Chu SY, Yue C, et al. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. Lancet Infect Dis. 2019. PMID: 30833160. doi:10.1016/S1473-3099(18)30650-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。